Kamran Muhammad is a Cardiology physician affiliated with Oklahoma Heart Institute. OpenAlex indexes 44 publications with 1,289 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Effects of Soft Tissue Mobilization Technique and Piriformis Muscle Stretching Among Patients Having Piriformis Syndrome
Sponsor: Neuro Counsel Hospital, Pakistan
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
142 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
142 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
61.9%Beta blocker15.3%Metoprolol Succinate73%Carvedilol15%Metoprolol Tartrate12%Part D<11 patientsStatin11.6%Atorvastatin Calcium90%Rosuvastatin Calcium10%Part D<11 patients+ 9 more classes in this area
Blood & clotting
28.1%P2Y12 inhibitor21.3%Clopidogrel96%Brilinta4%Part D<11 patientsFactor Xa inhibitor5.6%Eliquis85%Xarelto16%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
10%Potassium supplement4.1%Potassium Chloride100%Part D≥15 patientsSGLT2 inhibitor2.8%Jardiance51%Farxiga49%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immediate Coronary Angiography for STEMI and Out-of-Hospital Cardiac Arrest
Journal of the American College of Cardiology
2026 - Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
European Heart Journal
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Gard, MD
Oklahoma Heart Institute
David Sandler, MD
Oklahoma Heart Institute
Alan Kaneshige, MD
Oklahoma Heart Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”